Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
View Patent ↗The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing sumatriptan, frovatriptan, or naratriptan that are used in inhalation therapy. In a method aspect of the present invention, sumatriptan, frovatriptan, or naratriptan is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of sumatriptan, frovatriptan, or naratriptan on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering sumatriptan, frovatriptan, or naratriptan through an inhalation route is provided which comprises: a) a thin coating of a sumatriptan, frovatriptan, or naratriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.
1. A dose form of sumatriptan comprising a condensation aerosol
formed by heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan and condensing the vapor to form a condensation aerosol
characterized by less than 10% sumatriptan degradation products by weight, and
an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.
2. A dose form of frovatriptan comprising a condensation aerosol
formed by heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan and condensing the vapor to form a condensation aerosol
characterized by less than 10% frovatriptan degradation products by weight, and
MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.
3. A dose form of naratriptan comprising of a condensation aerosol
formed heating a thin layer containing naratriptan, on a solid support, to produce a vapor of naratriptan and condensing the vapor to form a condensation aerosol
characterized by less than 10% naratriptan degradation products by weight, and
an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.
4. A method of producing a dose form of sumatriptan comprising a condensation aerosol, the method comprising:
a. heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan, and
b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.
5. A method of producing a dose form of frovatriptan comprising a condensation aerosol, the method comprising:
a. heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan, and
b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.
6. A method of producing a dose form of naratriptan comprising a condensation aerosol, the method form comprising:
a. heating a thin layer containing naratriptan on a solid support, to produce a vapor of naratriptan, and
b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.